SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 24, 1997
GENTA INCORPORATED
(Exact name of registrant as specified in its charter)
Commission file number 0-19635
Delaware 33-0326866
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization)
3550 General Atomics Court, San Diego, CA 92121
(Address of principal executive offices)
(Zip Code)
(619) 455-2700
(Registrant's telephone number, including area code)
<PAGE>
GENTA INCORPORATED
FORM 8-K
CURRENT REPORT
TABLE OF CONTENTS
Item 5. Other Events
Item 7. Exhibit
Signature
- 2 -
<PAGE>
ITEM 5. Other Events
On September 24, 1997, the Company issued the press release attached
hereto as Exhibit 99.1.
ITEM 7. Exhibit
99.1 Press Release dated September 24, 1997.
- 3 -
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENTA INCORPORATED
Date: September 24, 1997
/s/ Michael S. Weiss
-------------------------
Michael S. Weiss
Vice Chairman and
Member of the Board
- 4 -
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: Mary Ann Dunnell
Robinson Lerer & Montgomery
212-484-7797
GENTA APPOINTS THREE ADDITIONAL NEW DIRECTORS
SAN DIEGO, CA, September 24, 1997 -- Genta Incorporated (Nasdaq: GNTA) today
announced that its Board of Directors elected three new directors on September
23, 1997:
o Lawrence J. Kessel, M.D., FACP, a physician in private practice in
Philadelphia who is a diplomate in both internal medicine and
geriatric medicine, as well as a Fellow of the American College of
Physicians and a Certified Medical Director of Long-Term Nursing
Facilities. Dr. Kessel is affiliated with Chestnut Hill Hospital,
Roxborough Memorial Hospital and Chestnut Hill Rehabilitation Hospital
and serves as a clinical instructor at Jefferson Medical College. He
is a director of PolaRx, a privately held biotechnology company.
o Peter Salomon, M.D., a physician in private practice in internal
medicine in Boca Raton, Florida, who is both a diplomate in
gastroenterology and a Fellow of the American College of
Gastroenterology. Dr. Salomon is affiliated with Boca Raton Community
Hospital and Delray Hospital. He has done advanced research and
published extensively in the field of gastroimmunology. Dr. Salomon is
also a director of PolaRx.
o Harlan J. Wakoff, Vice President of the Media and Entertainment
Investment Banking Group at Furman Selz LLC. Mr. Wakoff was previously
affiliated with the investment banking groups at NatWest Markets and
at Kidder Peabody & Co.
"These appointments bring total membership of the Genta Board of Directors to
ten," stated Genta Chairman Donald G. Drapkin. "Together with our other recent
Board appointments and, as previously announced, the election of Ken Kasses as
Genta President and Chief Executive Officer - Genta now has enhanced strength in
business, medical and scientific expertise that will help us make the most of
this Company's exceptional potential."
- more-
<PAGE>
2
The statements contained in this press release that are not historical are
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of
1934, as amended, including statements regarding the expectations, beliefs,
intentions or strategies regarding the future. The Company intends that all
forward-looking statements be subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements reflect the Company's views as of the date they are made with respect
to future events, but are subject to many risks and uncertainties, which could
cause the actual results of the Company to differ materially from any future
results expressed or implied by such forward-looking statements. The Company
does not undertake to update any forward-looking statements.
Genta Incorporated (Nasdaq: GNTA) is a biopharmaceutical company whose strategy
consists of building a product and technology portfolio that represents varying
degrees of development risk and market potential, including Anticode(TM)
(antisense) products intended to treat cancer at its genetic source, oral
controlled-release drugs and other genomics opportunities.
# # # #
